
Pfizer's Biologics License Application (BLA) for marstacimab, an anti-tissue factor pathway inhibitor for hemophilia A/B, has been accepted by the FDA, with a PDUFA action date in Q4 2024. The European application is under EMA review, expecting a decision in Q1 2025. Marstacimab, a potential once-weekly subcutaneous treatment, may offer a convenient alternative to intravenous infusions for hemophilia patients if approved
Like
Save
Share